Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma has announced its full-year financial results for 2025, showcasing ongoing advancements in its clinical trials. The Phase 1 trial evaluating the innovative GTB-3650 TriKE ® continues to actively enroll participants. Important updates regarding the trial are expected in Q3 2026 after the completion of enrollment in dose Cohort 5.
- GT Biopharma reports significant milestones in their ongoing studies.
- Next update on GTB-3650 TriKE ® anticipated within a year.
- Continued enrollment indicates strong confidence in product development.
- Key metrics expected to be released alongside future projections.
Why it matters: Investors should watch for further updates as they could provide insights into the company’s future growth prospects and potential market advantages.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.